MMIT Analytics, as of 3/28/19
Tuesday, April 2, 2019
Novartis’ Sandoz last week launched the...
...first generic for United
Therapeutics’ Remodulin, a pulmonary arterial hypertension drug. The brand drug
is covered on the pharmacy benefit for 44% of covered lives, and is found on
the preferred tier for 10% of those lives. Remodulin’s global revenue was $599
million in 2018.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment